News

The trial will focus on investigating the tolerability, safety, and therapeutic efficacy of multiple doses of 131I-TM601 when administered intravenously. This study follows the clinical confirmation in a

The company intends to close all of the sales on October 3, 2008. As of September 29, 2008, excluding any proceeds from this offering, Repros had cash and

Elite will manufacture the product and will receive a share of the profits from the sale of the product upon commercialization. Bernard Berk, chairman and CEO for Elite,

The board of directors also announced the appointment of Anthony Marucci, who has been serving as interim president and CEO since May 2008, as president and CEO of

Mr Keith is emeritus professor of obstetrics and gynecology at Northwestern University where he had taught more than 5000 medical students in a period of 29 years. Jim

The company said that the pivotal study is a multi-center US and EU evaluation of the Freedom Lumbar Disc in skeletally mature patients with single-level degenerative disc disease

Mr Lawson is responsible for expanding the company’s investor relations program to strengthen shareholder and analyst relations and ultimately grow the company’s shareholder base. Mr Lawson is based

Sun Pharmaceutical will use FEI’s 3D imaging solution for quality control of drug-loaded vesicles to speed up the development of new therapeutics. Cryo-transmission electron microscope (TEM) allows life

This marks the third US indication for Alimta. In 2004, Alimta has received consecutive approvals: first in combination with cisplatin as a treatment for patients with malignant pleural